On 21 September 2026, Sandoz Group AG joined the Swiss Market Index (SMI), Switzerland’s leading blue-chip equity index. The milestone was foreshadowed in an announcement by Sandoz on 9 July 2026 and comes less than three years after Sandoz became an independent publicly listed company.
The SMI comprises the 20 largest and most liquid stocks listed on the SIX Swiss Exchange and is widely regarded as the benchmark index for Swiss equities. Other pharmaceutical companies on the SMI are Novartis AG and Roche Holding AG. Dermatology focussed company, Galderma, also began trading on the SMI on 21 September 2026.
Sandoz recently announced that it is aiming to establish a portfolio of more than 100 biosimilars by 2040 as part of its Bio100 plan to maximise value in the “golden decade” for biosimilars.